Barclays Remains Bullish on Vertex (VRTX); Upside to Phase I Data

Article Stock Quotes (3) Comments (0)

Barclays maintains an 'Overweight' on Vertex (NASDAQ: VRTX) price target of $77.00.

Analyst, Ying Huang, said, "We remain bullish as we see upside from Phase I data of the Alios nucleotide HCV polymerase inhibitors (nucs). Next key catalyst lies in the data of Kalydeco/VX-809 in cystic fibrosis patients with heterozygous F508del mutation in July."

Huang thinks Vertex's nucs are similar to the Gilead (Nasdaq: GILD) / Bristol Myers (NYSE: BMY) nucs in structure.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $64.09 yesterday, with a 52 week range of $26.50-$66.10.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• Needham & Company Boosts PT on Pandora (P), Sees 23% Upside
• Best Buy (BBY) Numbers Raised at Jefferies Post Q1

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?